EGFR and neoplasm: Unlike categorical biomarkers for oncogene-addicted NSCLC such as epidermal growth factor receptor (EGFR), PD-L1 as an immunotherapy biomarker is continuous, spatially and temporally variable, and impacted by complex immune machinery in the tumor immune microenvironment (TIME) [11].